In Reply We studied the US Food and Drug Administration’s (FDA’s) oversight and management of an industry-funded prescriber education program aimed at improving prescriber practices and reducing adverse events from use of prescription opioids.1 Five years into the Risk Evaluation and Mitigation Strategy (REMS) program governing extended release/long-acting (ER/LA) opioids, the FDA was unable to evaluate the effect of the REMS on prescribing behavior or safety outcomes.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Heyward J, Sharfstein J, Alexander GC. Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program—Reply. JAMA Intern Med. 2020;180(6):916. doi:10.1001/jamainternmed.2020.1112
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: